Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review
- PMID:35313863
- PMCID: PMC8939098
- DOI: 10.1186/s12905-022-01657-6
Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review
Abstract
Objective: Levonorgestrel-releasing intrauterine devices (LNG-IUDs) and copper intrauterine devices (Cu-IUDs) offer long-acting contraception; however, some women may discontinue use within the first year due to bleeding pattern changes, limiting their potential. This systematic literature review investigated whether differences in bleeding profiles influence continuation rates in women in America, Europe and Australia.
Methods: Searches performed in PubMed and Embase were screened to identify publications describing bleeding patterns and rates of early IUC removal/discontinuation or continuation, descriptions of bleeding patterns, reasons for discontinuation, and patient satisfaction, acceptability and tolerability for LNG-IUDs and Cu-IUDs published between January 2010 and December 2019. The results were further restricted to capture citations related to 'Humans' and 'Females'. The review was limited to studies published from 2010 onwards, as changing attitudes over time mean that results of studies performed before this date may not be generalizable to current practice.
Results: Forty-eight publications describing 41 studies performed principally in the USA (n = 17) and Europe (n = 13) were identified. Publications describing bleeding patterns in LNG-IUD users (n = 11) consistently observed a reduction in bleeding in most women, whereas two of three studies in Cu-IUD users reported heavy bleeding in approximately 40% of patients. Rates of discontinuation for both devices ranged widely and may be as high as 50% but were lower for LNG-IUDs versus Cu-IUDs. Discontinuation rates due to bleeding were consistently higher for Cu-IUDs versus LNG-IUDs.
Conclusions: Bleeding is a common reason for discontinuation of Cu-IUDs and LNG-IUDs. The more favourable bleeding pattern observed in LNG-IUD users may be associated with a lower rate of early discontinuation of LNG-IUDs versus Cu-IUDs.
Keywords: Contraception; Discontinuation; Intrauterine device; Menstrual bleeding; Satisfaction.
© 2022. The Author(s).
Conflict of interest statement
DC has received grants and personal fees from Bayer AG, Merck and Allergan. RC is an employee of Accuscript Consultancy, Ludhiana, Punjab, India. RH is an employee of Accuscript Consultancy, Reading, Berkshire, UK. ST has served on scientific advisory boards for Allergan and Bayer AG. MM is an employee of Bayer AG, Berlin, Germany. Accuscript Consultancy was paid a fee for the conduct of the initial literature search and analysis.
Figures



Similar articles
- Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.Kaislasuo J, Heikinheimo O, Lähteenmäki P, Suhonen S.Kaislasuo J, et al.Hum Reprod. 2015 Jul;30(7):1580-8. doi: 10.1093/humrep/dev102. Epub 2015 May 19.Hum Reprod. 2015.PMID:25990577
- Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.Suvisaari J, Lähteenmäki P.Suvisaari J, et al.Contraception. 1996 Oct;54(4):201-8. doi: 10.1016/s0010-7824(96)00189-8.Contraception. 1996.PMID:8922872Clinical Trial.
- Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D, Robinson A, Proctor T, Summerbell C, Logan S, Helmerhorst F, Guillebaud J.French R, et al.Cochrane Database Syst Rev. 2004;2004(3):CD001776. doi: 10.1002/14651858.CD001776.pub2.Cochrane Database Syst Rev. 2004.PMID:15266453Free PMC article.Review.
- An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.Chi IC.Chi IC.Contraception. 1991 Dec;44(6):573-88. doi: 10.1016/0010-7824(91)90078-t.Contraception. 1991.PMID:1773615Review.
- A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.Modesto W, Bahamondes MV, Bahamondes L.Modesto W, et al.Hum Reprod. 2014 Jul;29(7):1393-9. doi: 10.1093/humrep/deu089. Epub 2014 May 8.Hum Reprod. 2014.PMID:24812309Clinical Trial.
Cited by
- Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims.Nguyen BT, Heyrana K, Ohsfeldt R, Johnston A, Summers K.Nguyen BT, et al.J Manag Care Spec Pharm. 2023 Dec;29(12):1303-1311. doi: 10.18553/jmcp.2023.29.12.1303.J Manag Care Spec Pharm. 2023.PMID:38058139Free PMC article.
- Continuation of Reversible Contraception Following Enrollment in the Zika Contraception Access Network (Z-CAN) in Puerto Rico, 2016-2020.Zapata LB, Kortsmit K, Curtis KM, Romero L, Hurst S, Lathrop E, Acosta Perez E, Sánchez Cesáreo M, Whiteman MK.Zapata LB, et al.Stud Fam Plann. 2024 Jun;55(2):105-125. doi: 10.1111/sifp.12262. Epub 2024 Apr 24.Stud Fam Plann. 2024.PMID:38659169Free PMC article.
- The use of LNG-IUS-19.5 mg in daily gynecological routine practice in Germany: data from the Kyleena™ Satisfaction Study (KYSS).Römer T, Frenz AK, Dietrich-Ott S, Fiedler A.Römer T, et al.Arch Gynecol Obstet. 2024 May;309(5):2021-2030. doi: 10.1007/s00404-024-07421-5. Epub 2024 Feb 29.Arch Gynecol Obstet. 2024.PMID:38421421Free PMC article.
- Is there a difference in the clinical profile and outcome of women using levonorgestrel IUD for abnormal uterine bleeding and those using it for contraception?: A comparative cross-sectional study.Al Shukri M, Said M, Nair A, Mathew M, Gowri V.Al Shukri M, et al.Turk J Obstet Gynecol. 2024 Mar 4;21(1):7-14. doi: 10.4274/tjod.galenos.2024.51460.Turk J Obstet Gynecol. 2024.PMID:38440962Free PMC article.
- Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis.Yang S, Liu Y, Wen J, Sun Y, Ren F.Yang S, et al.Evid Based Complement Alternat Med. 2022 Jul 15;2022:1995472. doi: 10.1155/2022/1995472. eCollection 2022.Evid Based Complement Alternat Med. 2022.Retraction in:Evid Based Complement Alternat Med. 2023 Jun 21;2023:9856568. doi: 10.1155/2023/9856568.PMID:35873621Free PMC article.Retracted.
References
- Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17(1):121–137. - PubMed
- U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013;62:1–60. - PubMed
- Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30. - PubMed
- Bayer HealthCare Pharmaceuticals Inc. Mirena Prescribing Information. October 2009.https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021225s027lbl.pdf. Accessed Jan 2021.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources